(Reuters) – Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary goals of a pivotal trial in patients with a neurological disorder called Fragile X syndrome.
Fragile X syndrome (FXS) is characterized by mild-to-moderate intellectual disability.
(Reporting By Mrinalika Roy in Bengaluru; Editing by Maju Samuel)
